Logo do repositório

In silico drug design strategies for discovering novel tuberculosis therapeutics

dc.contributor.authorCanales, Christian S. Carnero [UNESP]
dc.contributor.authorPavan, Aline Renata [UNESP]
dc.contributor.authordos Santos, Jean Leandro [UNESP]
dc.contributor.authorPavan, Fernando Rogério [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionSanta Maria Catholic University
dc.date.accessioned2025-04-29T18:37:15Z
dc.date.issued2024-01-01
dc.description.abstractIntroduction: Tuberculosis remains a significant concern in global public health due to its intricate biology and propensity for developing antibiotic resistance. Discovering new drugs is a protracted and expensive endeavor, often spanning over a decade and incurring costs in the billions. However, computer-aided drug design (CADD) has surfaced as a nimbler and more cost-effective alternative. CADD tools enable us to decipher the interactions between therapeutic targets and novel drugs, making them invaluable in the quest for new tuberculosis treatments. Areas covered: In this review, the authors explore recent advancements in tuberculosis drug discovery enabled by in silico tools. The main objectives of this review article are to highlight emerging drug candidates identified through in silico methods and to provide an update on the therapeutic targets associated with Mycobacterium tuberculosis. Expert opinion: These in silico methods have not only streamlined the drug discovery process but also opened up new horizons for finding novel drug candidates and repositioning existing ones. The continued advancements in these fields hold great promise for more efficient, ethical, and successful drug development in the future.en
dc.description.affiliationSchool of Pharmaceutical Science São Paulo State University (UNESP)
dc.description.affiliationSchool of Pharmacy biochemistry and biotechnology Santa Maria Catholic University
dc.description.affiliationUnespSchool of Pharmaceutical Science São Paulo State University (UNESP)
dc.format.extent471-491
dc.identifierhttp://dx.doi.org/10.1080/17460441.2024.2319042
dc.identifier.citationExpert Opinion on Drug Discovery, v. 19, n. 4, p. 471-491, 2024.
dc.identifier.doi10.1080/17460441.2024.2319042
dc.identifier.issn1746-045X
dc.identifier.issn1746-0441
dc.identifier.scopus2-s2.0-85186257534
dc.identifier.urihttps://hdl.handle.net/11449/298482
dc.language.isoeng
dc.relation.ispartofExpert Opinion on Drug Discovery
dc.sourceScopus
dc.subjectanti-tubercular compounds
dc.subjectcomputer-aided drug design
dc.subjectdrug discovery
dc.subjectligand-based drug design
dc.subjectmolecular docking
dc.subjectstructure-based drug design
dc.subjectTuberculosis
dc.titleIn silico drug design strategies for discovering novel tuberculosis therapeuticsen
dc.typeResenhapt
dspace.entity.typePublication
relation.isOrgUnitOfPublication95697b0b-8977-4af6-88d5-c29c80b5ee92
relation.isOrgUnitOfPublication.latestForDiscovery95697b0b-8977-4af6-88d5-c29c80b5ee92
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Ciências Farmacêuticas, Araraquarapt

Arquivos